(News Bulletin 247) – Resumption of quotation in strong rise for the manufacturer of medical devices. Monday, Biocorp announced its acquisition by the Danish giant Novo Nordisk for an amount of 154 million euros.

Suspended on Monday, Biocorp’s listing resumed sharply higher. The action of the French designer of medical devices jumped 15.70% to 33.90 euros, Tuesday morning around 10:30 am.

The title evolves not far from the 35 euros per share offered by Novo Nordisk within the framework of exclusive negotiations for the acquisition of a controlling stake in Biocorp.

Following this takeover, Novo Nordisk will file a draft simplified takeover bid (OPAS) with the Autorité des marchés financiers (AMF) in September, on the balance of the shares in circulation on the Stock Exchange. of Paris, still at a price of 35 euros per share.

The price offered by Novo Nordisk thus represents “a premium of 19.5% compared to Biocorp’s market closing price on June 2, 2023, – i.e. 29.30 euros – and 45.2%” over the last three months . The Danish group’s offer values ​​Biocorp’s capital at 154 million euros.

If the operation is successful, Novo Nordisk plans to withdraw the company from the Paris market. Biocorp had made its first steps on the stock market in July 2015 at a price of 9.25 euros, when Euronext Growth was still called Alternext.